系统性硬化症相关间质性肺病:如何在临床实践中整合两种FDA批准疗法
本综述聚焦系统性硬化症相关间质性肺病(SSc-ILD)的诊断与治疗,回顾了相关研究,并基于疾病严重程度(亚临床 vs 临床ILD)和进展风险(低 vs 高)提出实用的分类方法。文章讨论了已获FDA批准用于延缓SSc-ILD肺功能下降的尼达尼布和托珠单抗,以及未获FDA批准但II期试验显示效力的霉酚酸酯和环磷酰胺,并提出了诊断、分层、管理和治疗决策的实用路径。
要点
- 尼达尼布和托珠单抗获FDA批准用于延缓SSc-ILD肺功能下降。
- 霉酚酸酯和环磷酰胺在II期试验中效力相当,但未获FDA批准用于SSc-ILD。
- 按亚临床/临床ILD及低/高风险对SSc患者分层,指导一线、二线及联合治疗决策。
核心结论
- SSc-ILD的最佳治疗策略尚未确定,但尼达尼布和托珠单抗已获FDA批准用于延缓肺功能下降,霉酚酸酯和环磷酰胺在II期试验中显示可比效力但未获批。
研究设计与样本
- 本综述回顾了聚焦SSc-ILD诊断与治疗的研究,并基于疾病严重程度(亚临床 vs 临床ILD)和进展风险(低 vs 高)提出实用分类方法。
主要发现
- SSc是所有风湿病中个体死亡率最高的疾病,ILD是SSc相关死亡的主要原因之一。
- 尼达尼布(酪氨酸激酶抑制剂)和托珠单抗(首个靶向IL-6通路的生物制剂)获FDA批准用于延缓SSc-ILD患者肺功能下降速率。
- 霉酚酸酯和环磷酰胺(具有细胞毒和免疫调节活性的仿制药)在II期试验中显示可比效力,但未获FDA批准用于SSc-ILD。
关键数值与推荐
- FDA批准尼达尼布和托珠单抗用于延缓SSc-ILD患者肺功能下降。
- II期试验显示霉酚酸酯和环磷酰胺效力相当,但未获FDA批准用于SSc-ILD。
临床怎么用
- 基于疾病严重程度(亚临床 vs 临床ILD)和进展风险(低 vs 高)对SSc患者分层,以指导一线、二线及潜在联合治疗决策。
局限性
- 由于疾病异质性,SSc-ILD的最佳治疗策略仍待确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic sclerosis (SSc; scleroderma) has the highest individual mortality of all rheumatic diseases, and interstitial lung disease (ILD) is among the leading causes of SSc-related death. Two drugs are now approved by the US Food and Drug Administration (FDA) and indicated for slowing the rate of decline in pulmonary function in patients with SSc-associated ILD (SSc-ILD): nintedanib (a tyrosine kinase inhibitor) and tocilizumab (the first biologic agent targeting the interleukin-6 pathway in SSc). In addition, 2 generic drugs with cytotoxic and immunoregulatory activity, mycophenolate mofetil and cyclophosphamide, have shown comparable efficacy in a phase II trial but are not FDA-approved for SSc-ILD. In light of the heterogeneity of the disease, the optimal therapeutic strategy for the management of SSc-ILD is still to be determined. The objectives of this review are 2-fold: 1) review the body of research focused on the diagnosis and treatment of SSc-ILD; and 2) propose a practical approach for diagnosis, stratification, management, and therapeutic decision-making in this clinical context. This review presents a practical classification of SSc patients in terms of disease severity (subclinical versus clinical ILD) and associated risk of progression (low versus high risk). The pharmacologic and nonpharmacologic options for first- and second-line therapy, as well as potential combination approaches, are discussed in light of the recent approval of tocilizumab for SSc-ILD.
引用
- Khanna D, Lescoat A, Roofeh D, et al. Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice. Arthritis Rheumatol. 2021. PMID: 34313399. doi:10.1002/art.41933
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。